Cited by 826Atrial Fibrillation Management and OutcomesBlood Pressure and Hypertension StudiesCardiac electrophysiology and arrhythmias

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol

Open access

Wachtell, Kristian, Lehto, Mika, Gerdts, Eva, Olsen, Michael H., Hornestam, Björn, Dahlöf, Björn, Ibsen, Hans, Julius, Stevo, Kjeldsen, Sverre E., Lindholm, Lars H., Nieminen, Markku S., Devereux, Richard B.·2005·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2004.10.068

Open this paper in CoChat — free account Open PDF

Abstract

Objectives This study was designed to evaluate whether different antihypertensive treatment regimens with similar blood pressure reduction have different effects on new-onset atrial fibrillation (AF).Background It is unknown whether angiotensin II receptor blockade is better than beta-blockade in preventing new-onset AF.Methods In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy. Electrocardiograms were Minnesota coded centrally, and 8,851 patients without AF by electrocardiogram or history, who were thus at risk of developing AF, were followed for 4.8 +/- 1.0 years.Results New-onset AF occurred in 150 patients randomized to losartan versus 221 to atenolol (6.8 vs. 10.1 per 1,000 person-years; relative risk 0.67, 95% confidence interval [CI] 0.55 to 0.83, p < 0.001) despite similar blood pressure reduction. Patients receiving losartan tended to stay in sinus rhythm longer (1,809 +/- 225 vs. 1,709 +/- 254 days from baseline, p = 0.057) than those receiving atenolol. Moreover, patients with new-onset AF had two-, three- and fivefold increased rates, respectively, of cardiovascular events, stroke, and hospitalization for heart failure. There were fewer composite end points (n = 31 vs. 51, hazard ratio = 0.60, 95% CI 0.38 to 0.94, p = 0.03) and strokes (n = 19 vs. 38, hazard ratio = 0.49, 95% CI 0.29 to 0.86, p = 0.01) in patients who developed new-onset AF in the losartan compared to the atenolol treatment arm of the study. Furthermore, Cox regression analysis showed that losartan (21% risk reduction) and new-onset AF both independently predicted stroke even when adjusting for traditional risk factors.Conclusions Our novel finding is that new-onset AF and associated stroke were significantly reduced by losartan- compared to atenolol-based antihypertensive treatment with similar blood pressure reduction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2004.10.068

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citation
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study
Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. V. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01236-6 · Cited by 1,562
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary
Fuster, V., Rydén, L., ASINGER, R. W., Cannom, D. S., Crijns, H. J. G. M., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Lévy, S., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01587-x · Cited by 1,362
Left Atrial Size and the Risk of Stroke and Death
Benjamin, E. J., D’Agostino, R. B., Belanger, A. J., Wolf, P. A., & Levy, D. A. (1995) · Circulation · doi:10.1161/01.cir.92.4.835 · Cited by 1,058
Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing–Induced Congestive Heart Failure
Li, D., Shinagawa, K., Pang, L., Leung, T. K., Cardin, S., Wang, Z., & Nattel, S. (2001) · Circulation · doi:10.1161/hc4601.099402 · Cited by 702
Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study
Madrid, A. H., Bueno, M. G., Rebollo, J. M. G., Marín, I., Peña, G., Bernal, E., Rodriguez, A., Cano, L., Cano, J. M., Cabeza, P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000022665.18619.83 · Cited by 685
Trandolapril Reduces the Incidence of Atrial Fibrillation After Acute Myocardial Infarction in Patients With Left Ventricular Dysfunction
Pedersen, O. D., Bagger, H., Køber, L., & Torp-Pedersen, C. T. (1999) · Circulation · doi:10.1161/01.cir.100.4.376 · Cited by 656
Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction
Vermès, E., Tardif, J., Bourassa, M. G., Racine, N., Lévesque, S., White, M., Guerra, P. G., & Ducharme, A. (2003) · Circulation · doi:10.1161/01.cir.0000072793.81076.d4 · Cited by 575
Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation
Kumagai, K., Nakashima, H., Urata, H., Gondo, N., Arakawa, K., & Saku, K. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00464-9 · Cited by 472

Flagged first, then by citations

Show all 27 references

Sorted by citations

Items 401–500 of 819

Atrial fibrillation in heart failure patients: An update on renin–angiotensin–aldosterone system pathway blockade as a therapeutic and prevention target
Koniari, I. C., Artopoulou, E., Mplani, V., Mulita, F., Alexopoulou, E., Chourdakis, E., Abo-Elseoud, M., Tsigkas, G., Panagiotopoulos, I. A., Kounis, N. G., et al. (2022) · Cardiology Journal · doi:10.5603/cj.a2022.0061 · Cited by 14
Renin‐Angiotensin System Blocker Use May Be Associated with Suppression of Atrial Fibrillation Recurrence after Pulmonary Vein Isolation
Ishikawa, K., Yamada, T., Yoshida, Y., Takigawa, M., Aoyama, Y., Inoue, N., Tatematsu, Y., Nanasato, M., Kato, K., Tsuboi, N., et al. (2010) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2010.02949.x · Cited by 14
Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide
Flack, J. M. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01577.x · Cited by 14
Manejo de los pacientes con fibrilación auricular en los servicios de urgencias hospitalarios (actualización 2012)
Martı́n, A., Lozano, I. F., Puig, B. C.-V., Tercedor, L., del Arco, C., Ynsaurriaga, F. A., Méndez, C. S., & Girbau, L. M. (2012) · Emergencias · Cited by 14
Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: The LIFE Study
Ariansen, I., Reims, H. M., Gjesdal, K., Olsen, M. H., Ibsen, H., Devereux, R. B., Okin, P. M., Kjeldsen, S. E., Dahlöf, B., & Wachtell, K. (2011) · Blood Pressure · doi:10.3109/08037051.2011.622978 · Cited by 14
Self-citation
Contrasting Hemodynamic Mechanisms of Losartan- vs. Atenolol-Based Antihypertensive Treatment: A LIFE Study
Greve, A. M., Olsen, M. H., Bella, J. N., Lønnebakken, M. T., Gerdts, E., Okin, P. M., Palmieri, V., Boman, K., Nieminen, M. S., Omvik, P., et al. (2012) · American Journal of Hypertension · doi:10.1038/ajh.2012.81 · Cited by 14
Self-citation
Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension
Tocci, G., Sciarretta, S., Facciolo, C., & Volpe, M. (2007) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.5.4.767 · Cited by 14
Risk for Incident Atrial Fibrillation in Patients Who Receive Antihypertensive Drugs: A Nested Case–Control Study
Elliott, W. J. (2011) · Yearbook of Cardiology · doi:10.1016/j.ycar.2011.01.066 · Cited by 14
Will Warfarin Soon Be Passé? New Approaches to Stroke Prevention in Atrial Fibrillation
Hammwöhner, M., & Goette, A. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318177e1f2 · Cited by 14
Angiotensin II inhibition and prevention of atrial fibrillation and stroke**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Bourassa, M. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.12.008 · Cited by 14
Metabolic Dysfunction-Associated Steatotic Liver Disease as a Cardiovascular Risk Factor: Focus on Atrial Fibrillation
Awashra, A., Nouri, A., Hamdan, A., Said, H., Rajab, I. M., Hussein, A. H., & Rmilah, A. A. A. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000932 · Cited by 13
Upstream Effect for Atrial Fibrillation: Still a Dilemma?
Calò, L., Martino, A., Sciarra, L., Ciccaglioni, A., Ruvo, E. D., Luca, L. D., Sette, A., Giunta, G., Lioy, E., & Fedele, F. (2010) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2010.02942.x · Cited by 13
Correlation between aortic stiffness and left atrial volume index in hypertensive patients
Janwanishstaporn, S., & Boonyasirinant, T. (2015) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2015.1081211 · Cited by 13
Management of patients with arterial hypertension and atrial fibrillation
Chazova, I. E., Голицын, С. П., Zhernakova, Y. V., Zheleznova, E. A., Станиславовна, К. Е., Миронов, Н. Ю., Kostyukevich, M. V., Laiovich, L. I., Utsumueva, M. D., Александровна, Ю. Ю., et al. (2021) · Systemic Hypertension · doi:10.26442/2075082x.2021.3.201077 · Cited by 13
Association of Nondihydropyridine Calcium Channel Blockers Versus β-Adrenergic Receptor Blockers With Risk of Heart Failure Hospitalization
Meyer, M., Wetmore, J. B., Weinhandl, E. D., & Roetker, N. S. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.04.013 · Cited by 13
Prevalence of Atrial Fibrillation and Use of Antithrombotics in Hypertensive Patients Aged ≥65 Years. The FAPRES Trial
Morillas, P., Pallarés‐Carratalá, V., Llisterri, J. L., Sanchís, C., Sánchez, T., Fácila, L., Pérez‐Alonso, M., Castillo, J., Redón, J., & Bertoméu, V. (2010) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(10)70188-2 · Cited by 13
What do we actually know about the relationship between arterial hypertension and atrial fibrillation?
Tadic, M. V., Ivanovic, B. A., & Cuspidi, C. (2013) · Blood Pressure · doi:10.3109/08037051.2013.814234 · Cited by 13
Renin-angiotensin-system modulators and the incidence of atrial fibrillation following hospitalization for coronary artery disease
Singh, J. P., Kulik, A., Levin, R., Ellinor, P. T., Ruskin, J. N., Avorn, J., & Choudhry, N. K. (2012) · EP Europace · doi:10.1093/europace/eus074 · Cited by 13
Different effects of norepinephrine and nerve growth factor on atrial fibrillation vulnerability
Yang, M., Zhang, S., Liang, J., Tang, Y., Wang, X., Huang, C., & Zhao, Q. (2019) · Journal of Cardiology · doi:10.1016/j.jjcc.2019.04.009 · Cited by 13
Atrial fibrillation and heart failure with preserved ejection fraction “twindemic”—Shared root causes and treatment targets
Habel, N., Infeld, M. M., Lustgarten, D. L., & Meyer, M. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.08.064 · Cited by 15
Comparison of the effects of quinapril and irbesartan on P-wave dispersion in hypertensive patients
Güntekin, Ü., Güneş, Y., Tuncer, M., Şimşek, H., & Güneş, A. K. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0083-1 · Cited by 12
Recent Clinical Trials in Atrial Fibrillation in Hypertensive Patients
Manolis, A. J., Kallistratos, M. S., & Poulimenos, L. E. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0268-5 · Cited by 12
Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?
Weber, M. A. (2009) · Journal of Hypertension · doi:10.1097/01.hjh.0000357903.93951.73 · Cited by 12
Choices for long-term hypertensive control in patients after first-ever hemorrhagic stroke: a nationwide cohort study
Liu, C., Lin, Y., Chi, C., Liou, C., Lee, J.-D., Peng, T., & Lee, T. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418802688 · Cited by 12
Association Between Plasma Intact Parathyroid Hormone Levels and the Prevalence of Atrial Fibrillation in Patients With Chronic Kidney Disease ― The Fukuoka Kidney Disease Registry Study ―
Arase, H., Yamada, S., Tanaka, S., Tokumoto, M., Tsuruya, K., Nakano, T., & Kitazono, T. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-1201 · Cited by 12
Atrial fibrillation in severe aortic valve stenosis — Association with left ventricular left atrial remodeling
Dahl, J. S., Brandes, A., Videbæk, L. M., Poulsen, M. K., Carter‐Storch, R., Christensen, N. L., Banke, A., Pellikka, P. A., & Møller, J. E. (2014) · IJC Heart & Vessels · doi:10.1016/j.ijchv.2014.06.006 · Cited by 12
The pharmaceutical pipeline for atrial fibrillation
Santangeli, P., Biase, L. D., Pelargonio, G., Burkhardt, J. D., & Natale, A. (2010) · Annals of Medicine · doi:10.3109/07853890.2010.538431 · Cited by 12
Differences in pharmacology and their translation into differences in clinical efficacy – a comparison of the renin angiotensin blocking agents irbesartan and losartan
Bramlage, P., & Schindler, C. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903512962 · Cited by 12
Advances in mechanisms of atrial fibrillation: structural remodeling, high-frequency fractionated electrograms, and reentrant AF drivers
Makati, K. J., Alsheikh-Ali, A. A. A., Garlitski, A. C., Link, M. S., Homoud, M. K., Weinstock, J., & Estes, N. A. M. (2008) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-008-9256-8 · Cited by 12
Atrial Fibrillation and Flutter
Brady, P. A., & Gersh, B. J. (2007) · Springer eBooks · doi:10.1007/978-1-84628-715-2_95 · Cited by 12
Of hammers and screws: renin-angiotensin-aldosterone system inhibition to prevent atrial fibrillation in patients with hypertension
Kirchhof, P. F., & Fabritz, L. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu068 · Cited by 12
Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial
on behalf of the J-ROCKET AF Study Investigators, Matsumoto, M., Hori, M., Tanahashi, N., Momomura, S., Uchiyama, S., Goto, S., Izumi, T., Koretsune, Y., Kajikawa, M., et al. (2014) · Hypertension Research · doi:10.1038/hr.2014.1 · Cited by 11
Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry
Fudim, M., Liu, P. R., Shrader, P. J., Blanco, R. G., Allen, L. A., Fonarow, G. C., Gersh, B. J., Kowey, P. R., Mahaffey, K. W., Hylek, E. M., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007987 · Cited by 11
Left atrial pathological degeneration assessed by integrated backscatter transesophageal echocardiography as a predictor of progression to persistent atrial fibrillation: Results from a prospective study of three-years follow-up
Kubota, T., Kawasaki, M., Takasugi, N., Imai, H., Ishihara, Y., Okubo, M., Takahashi, S., Sato, H., Nishigaki, K., Takemura, G., et al. (2012) · Cardiovascular Ultrasound · doi:10.1186/1476-7120-10-28 · Cited by 11
Effects of candesartan, an angiotensin II receptor type I blocker, on atrial remodeling in spontaneously hypertensive rats
Choisy, S. C. M., Kim, S., Hancox, J. C., Jones, S. A., & James, A. F. (2015) · Physiological Reports · doi:10.14814/phy2.12274 · Cited by 11
Antiarrhythmic Drug Therapy for Atrial Fibrillation
Sardar, M. R., Saeed, W., & Kowey, P. R. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2014.07.012 · Cited by 11
Risk Factors for New-Onset Atrial Fibrillation During Routine Medical Checkups of Japanese Male Workers
Minami, M., Kobayashi, Y., Toyokawa, S., Inoue, K., & Takeshita, Y. (2009) · International Heart Journal · doi:10.1536/ihj.50.457 · Cited by 11
Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy
Bose, A., Truong, Q. A., & Singh, J. P. (2015) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-015-9982-7 · Cited by 11
Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat
Máťuš, M., Kucerova, D., Kružliak, P., Adameová, A., Dóka, G., Turcekova, K., Kmecova, J., Kyselovič, J., Křenek, P., Kirchhefer, U., et al. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2350-1 · Cited by 11
Hipertensión arterial : diagnóstico, tratamiento y control
Crombet, J. S. (2008) · Cited by 11
Oxidative Stress and the Pathogenesis of Atrial Fibrillation
Iravanian, S., & Dudley, S. C. (2006) · Current Cardiology Reviews · doi:10.2174/157340306778772887 · Cited by 11
The Effects of Rate and Rhythm Control on Blood Pressure and Antihypertensive Drug Usage in Patients with Atrial Fibrillation and Hypertension Enrolled in the AFFIRM Trial
MASOOD, S. O., Wasmund, S. L., AKOUM, N. W., Egger, M. J., Hsiai, T. K., & Hamdan, M. H. (2010) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2010.01792.x · Cited by 10
Age and CHADS2 Score Predict the Effectiveness of Renin-Angiotensin System Blockers on Primary Prevention of Atrial Fibrillation
Hung, C.-Y., Hsieh, Y., Li, C.-H., Huang, J., Lin, C., & Wu, T. (2015) · Scientific Reports · doi:10.1038/srep11442 · Cited by 10
Antihypertensive therapy and cerebrovascular protection
Volpe, M., & Tocci, G. (2006) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000242175.59823.f2 · Cited by 10
Serum uric acid and atrial fibrillation
Manolis, A. J. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1378521 · Cited by 10
Secondary Prevention of Arterial Disease in Very Elderly People: Results From a Prospective Registry (FRENA)
López‐Jiménez, L., Camafort, M., Tiberio, G., Carmona, J. A., Guijarro, C., Martínez-Peñalver, F., Monréal, M., & FRENA Investigators (2008) · Angiology · doi:10.1177/0003319707309299 · Cited by 10
Prediction of Stroke Risk in Atrial Fibrillation, Prevention of Stroke in Atrial Fibrillation, and the Impact of Long-Term Monitoring for Detecting Atrial Fibrillation
Thomas, G., & Lerman, B. B. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0188-x · Cited by 10
Adaptive and Maladaptive Remodeling of Cardiomyocyte Excitation-Contraction Coupling by Angiotensin II
Egger, M., & Domenighetti, A. A. (2010) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2010.06.001 · Cited by 10
Blockade of the renin–angiotensin system in atrial fibrillation
Kuzniatsova, N., Shantsila, E., & Lip, G. Y. H. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.103 · Cited by 10
An Angiotensin Receptor Blocker Prevents Arrhythmogenic Left Atrial Remodeling in a Rat Post Myocardial Infarction Induced Heart Failure Model
Kim, H., No, C.-W., Goo, S.-H., & Cha, T. (2013) · Journal of Korean Medical Science · doi:10.3346/jkms.2013.28.5.700 · Cited by 10
Atrial Fibrillation: Pharmacological Therapy
Patel, C., Salahuddin, M., Jones, A., Patel, A., Yan, G., & Kowey, P. R. (2011) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2011.01.001 · Cited by 10
Arterial hypertension in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme pilot survey on atrial fibrillation
Dan, G., Bădilă, E., Weiss, E., Laroche, C., Boriani, G., Dan, A. R., Tavazzi, L., Maggioni, A. P., Crijns, H. J. G. M., Popescu, R. A., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.092 · Cited by 10
Increased Plasma Aldosterone during Atrial Fibrillation Declines following Cardioversion
Soeby-Land, C., Dixen, U., Therkelsen, S., & Kjær, A. (2011) · Cardiology · doi:10.1159/000328462 · Cited by 10
Combination of Irbesartan and Amiodarone to Maintain Sinus Rhythm in Patients With Persistent Atrial Fibrillation After Rheumatic Valve Replacement
Ji, Q., Mei, Y., Wang, X., Feng, J., Wusha, D., Cai, J., Sun, Y., & Xie, S. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0254 · Cited by 10
Drug Therapy for Atrial Fibrillation
Musco, S., Conway, E. L., & Kowey, P. R. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.08.002 · Cited by 10
The Future of Atrial Fibrillation Therapy
Dorian, P. (2006) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2006.00582.x · Cited by 10
Slower Heart Rates for Healthy Hearts
Gopinathannair, R., Sullivan, R. M., & Olshansky, B. (2008) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.108.835264 · Cited by 10
Editorial Comment: Secondary Prevention of Stroke Is Important
Strandberg, T. E. (2005) · Stroke · doi:10.1161/01.str.0000166044.06026.46 · Cited by 10
Non-Anticoagulation Strategies Aimed at Primary Stroke Prevention in Nascent Atrial Fibrillation
Sgarra, L., Desantis, V., Matteucci, A., Caccavo, V. P., Troisi, F., Monaco, A. D., Mangini, F., Katsouras, G., Guaricci, A. I., Dadamo, M. L., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13030660 · Cited by 9
Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers
Poulter, N. R., Hughes, A. D., Williams, B., Brady, A. J. B., & McInnes, G. T. (2006) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2006.008 · Cited by 9
Comparison of the Effect of Combination Therapy with an Angiotensin II Receptor Blocker and Either a Low-Dose Diuretic or Calcium Channel Blocker on Cardiac Hypertrophy in Patients with Hypertension
Okura, T., Miyoshi, K., Irita, J., Enomoto, D., Jotoku, M., Nagao, T., Watanabe, K., Matsuoka, H., Ashihara, T., Higaki, J., et al. (2013) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2013.764892 · Cited by 9
Eplerenone might affect atrial fibrosis in patients with hypertension
Kawasaki, M., Yamada, T., Okuyama, Y., Morita, T., Furukawa, Y., Tamaki, S., Iwasaki, Y., Kikuchi, A., Sakata, Y., & Fukunami, M. (2017) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.13169 · Cited by 9
Prevention of atrial fibrillation in patients with aortic valve stenosis with candesartan treatment after aortic valve replacement
Dahl, J. S., Videbæk, L. M., Poulsen, M. K., Pellikka, P. A., Veien, K. T., Andersen, L. I., Haghfelt, T. H., & Møller, J. E. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.08.056 · Cited by 9
Bradycardia and B-type natriuretic peptide
Kováts, T., & Tomcsányi, J. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.03.086 · Cited by 9
The Association between the PR Interval and Left Ventricular Measurements in the Multiethnic Study of Atherosclerosis
Husby, M. P., Soliman, E. Z., Goldberger, J. J., Liu, K., Lloyd‐Jones, D. M., Durazo-Arvizú, R., & Kramer, H. (2015) · Cardiology Research and Practice · doi:10.1155/2015/193698 · Cited by 9
Therapeutic potential of angiotensin receptor blockers in hypertension
Cheung, B. M. Y. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.6.625 · Cited by 10
Secondary prophylactic treatment and long‐term prognosis after TIA and different subtypes of stroke. A 25‐year follow‐up hospital‐based observational study
Eriksson, S. (2016) · Brain and Behavior · doi:10.1002/brb3.603 · Cited by 9
The Progressive Nature of Atrial Fibrillation:A Rationale for Early Restoration and Maintenance of Sinus Rhythm.
Shah, A. J., Hocini, M., Komatsu, Y., Daly, M. G., Zellerhoff, S., Jesel, L., Amaroui, S., Ramoul, K., Denis, A., Derval, N., et al. (2013) · Europe PMC (PubMed Central) · doi:10.4022/jafib.849 · Cited by 9
Factors Modifying the Risk of Atrial Fibrillation Associated With Atrial Premature Complexes in Patients With Hypertension
Soliman, E. Z., Howard, G., Judd, S. E., Bhave, P. D., Howard, V. J., & Herrington, D. M. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.02.006 · Cited by 10
Targeting the renin–angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Kjeldsen, S. E., Lyle, P. A., Tershakovec, A. M., Devereux, R. B., Oparil, S., Dahlöf, B., Fairé, U. D., Fyhrquist, F., Ibsen, H., Kristianson, K. J., et al. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.4.729 · Cited by 9
Self-citation
Smokeless tobacco country: from nicotine dependency to oral problems and cancer.
Christen, A. G., & McDonald, J. L. (1987) · PubMed · Cited by 9
Renin–angiotensin blockade in atrial fibrillation: where are we now?
Shahid, F., Lip, G. Y. H., & Shantsila, E. (2017) · Journal of Human Hypertension · doi:10.1038/jhh.2017.6 · Cited by 9
Aging diastole - root cause for atrial fibrillation and heart failure with preserved ejection fraction
Meyer, M., Núñez, J. E., Goyal, P., Silverman, D. N., van Berlo, J. H., & Maharaj, V. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.22 · Cited by 8
Impact of renin–angiotensin system inhibitors on outcomes after transcatheter aortic valve replacement: A meta‐analysis
Ying-hao, S. U. N., Li, J., Li, G., Fan, R., & Luo, J. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.28899 · Cited by 8
Beta Blockers in Contemporary Cardiology: Is It Better to Cast Them Out?
Dar, J. A., & Jacob, J. R. (2024) · Korean Circulation Journal · doi:10.4070/kcj.2023.0209 · Cited by 8
Adjuvant Therapy for Atrial Fibrillation
Mohammed, K., Kowey, P. R., & Musco, S. (2009) · Future Cardiology · doi:10.2217/fca.09.57 · Cited by 8
Effects of Atorvastatin on Serum High-Sensitive C-Reactive Protein and Total Cholesterol Levels in Asian Patients With Atrial Fibrillation
Wang, J., Wang, A.-R., Zhang, M., & Yu, L. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000344 · Cited by 8
Effect of ramipril/hydrochlorothiazide and ramipril/canrenone combination on atrial fibrillation recurrence in hypertensive type 2 diabetic patients with and without cardiac autonomic neuropathy
Bosone, D., Costa, A. C., Ghiotto, N., Ramusino, M. C., Zoppi, A., D’Angelo, A., & Fogari, R. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.62448 · Cited by 8
Actin-granule formation is an additional step in cardiac myofibroblast differentiation
He, L., Liu, R., Yue, H., Ren, S., Zhu, G., Guo, Y., & Qin, C. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-8231 · Cited by 8
Influence of body mass index on recurrence of atrial fibrillation after electrical cardioversion
Ligero, C., Bazán, V., Palmero, M. J. G., Rodríguez‐Mañero, M., Viñolas, X., & Alegret, J. M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291938 · Cited by 8
Drug Therapy for Atrial Fibrillation
Conway, E. L., Musco, S., & Kowey, P. R. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2008.10.003 · Cited by 8
Applied Healthspan Engineering
Larrick, J. W., & Mendelsohn, A. R. (2010) · Rejuvenation Research · doi:10.1089/rej.2009.0969 · Cited by 8
Losartan in Cardiovascular Disease
de Vogel, S., Hoorn, E. J., & Papademetriou, V. (2005) · Future Cardiology · doi:10.2217/14796678.1.4.433 · Cited by 8
Prospects for the prevention of stroke
Dahlöf, B. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000220097.04531.6f · Cited by 8
Self-citation
Hypertension, stroke and the impact of atrial fibrillation
Krishnamoorthy, S., & Lip, G. Y. H. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.10.1287 · Cited by 8
Circulating and local renin-angiotensin-aldosterone system express differently in atrial fibrillation patients with different types of mitral valvular disease
Yongjun, Q., Ying, L., Hong, T., Wenxia, Z., Jiang, L., Yong-bo, L., Li, N., Li, M., & Xijun, X. (2012) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320312460897 · Cited by 8
Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?
Karagiannis, A. I., Mikhailidis, D. P., Kakafika, A. I., Τζιόμαλος, Κ., & Athyros, V. G. (2006) · Current Pharmaceutical Design · doi:10.2174/138161207779313713 · Cited by 8
Upstream Therapy for Atrial Fibrillation in Heart Failure
Goette, A. (2013) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.07.010 · Cited by 8
Mineralocorticoid receptor, CYP11B2 mRNA expression, and atrial matrix remodelling in patients with atrial fibrillation
Pei, D.-A., Yan, Y.-Y., Li, L., Xu, Z., Huang, J., Wang, M., Xu, Z., Yao, Q., Huang, S.-E., Huang, Q., et al. (2010) · Acta cardiologica. Supplementum · doi:10.1080/ac.65.5.2056239 · Cited by 8
Prevalence, significance and reversal of abnormal P-wave indices in hypertension: A review and meta-analysis
Aizawa, Y., Sato, T., & Akazawa, K. (2018) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2018.12.008 · Cited by 8
Modifiable Risk Factors and Atrial Fibrillation: the Quest for a Personalized Approach
Matei, L.-L., Silişte, C., & Vinereanu, D. (2021) · MAEDICA – a Journal of Clinical Medicine · doi:10.26574/maedica.2020.16.1.88 · Cited by 8
Differential risks of stroke in pharmacotherapy on uncomplicated hypertensive patients?
Liu, P.-H., Hu, F.-C., & Wang, J. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283193a29 · Cited by 8
Estimated risk of a first stroke and conditioning factors in Spanish hypertensive women. The RIMHA study
Coca, A., Redón, J., Cea‐Calvo, L., Lozano, J. V., Navarro, J., Fernández, C., Bonet, A., & González‐Esteban, J. (2006) · Blood Pressure · doi:10.1080/08037050600913474 · Cited by 8
Candesartan: widening indications for this angiotensin II receptor blocker?
Mendis, B., & Page, S. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903092197 · Cited by 8
Elevada prevalencia de hipertrofia ventricular izquierda en pacientes con hipertensión arterial de larga evolución
Villaverde, J. M. F., Saavedra, F. J. M., Vidal, G., Shamagian, L. G., Otero-Raviña, F., & González‐Juanatey, J. R. (2007) · Medicina Clínica · doi:10.1157/13106936 · Cited by 8
Therapeutic implications of gender differences in supraventricular cardiac arrhythmias: lessons of life cannot be learned in a day
Deneke, T., Mügge, A., Müller, P., & de Groot, J. R. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.80 · Cited by 8
Características farmacológicas de los ARA-II. ¿Son todos iguales?
Tamargo, J. L., Caballero, R., Gómez, R. J., Núñez, L., Vaquero, M., & Delpón, E. (2006) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(06)75306-7 · Cited by 8
Does treatment of hypertension decrease the incidence of atrial fibrillation and cardioembolic stroke?
Solun, B., Marcoviciu, D., & Dicker, D. (2008) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2008.07.001 · Cited by 8
Prevention of Atrial Fibrillation by Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
Boos, C. J., & Lip, G. Y. H. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.033 · Cited by 8
Rac1 and Connective Tissue Growth Factor
Liao, J. K. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.071 · Cited by 8

Authors: Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., Nieminen, M. S., & Devereux, R. B.
Affiliations: Cornell University (US)
Helsinki University Hospital (FI)
Haukeland University Hospital (NO)
Glostrup Hospital (DK)
Sahlgrenska University Hospital (SE)
University of Michigan (US)
Oslo University Hospital (NO)
University Hospital of Umeå (SE)
Corresponding author: Wachtell, Kristian
ORCID: Wachtell, Kristian
Lehto, Mika
Gerdts, Eva
Olsen, Michael H.
Hornestam, Björn
Kjeldsen, Sverre E.
Lindholm, Lars H.
Nieminen, Markku S.
Devereux, Richard B.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2005-03
Volume: 45
Issue: 5
Pages: 712-719
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2004.10.068
OpenAlex: W2147918774
Cited by: 826
References: 27
Citations by year: 2026: 9 · 2025: 18 · 2024: 16 · 2023: 17 · 2022: 13 · 2021: 20 · 2020: 20 · 2019: 16 · 2018: 30 · 2017: 32 · 2016: 31 · 2015: 29 · 2014: 36 · 2013: 40 · 2012: 33
FWCI: 64.95
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3096 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Funders: Rigshospitalet
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords: angiotensin II receptor blockade, losartan, atenolol, beta-blockers, stroke prevention, hypertension, left ventricular hypertrophy, antihypertensive therapy, heart failure hospitalization, cardiovascular events, life studies, sinus rhythm maintenance, RAS inhibition, renin-angiotensin system
MeSH terms: Adrenergic beta-Antagonists, Aged, Aged, 80 and over, Atenolol, Atrial Fibrillation, Cause of Death, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Prospective Studies, Risk Factors, Survival Rate, Hypertrophy, Left Ventricular, Losartan, Stroke, Angiotensin II Type 1 Receptor Blockers, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks